BCNPEPTIDES
LIVE

Serial Number

79417535

Owner

BCN PEPTIDES, S.A.

Attorney

Elizabeth Lee D'Amore

Filing Date

Dec 24, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BCNPEPTIDES Trademark

Serial Number: 79417535

BCNPEPTIDES is a trademark filed by BCN PEPTIDES, S.A. on December 24, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

BCN PEPTIDES, S.A. (3 trademarks)

Ctra. Comarcal 244
Barcelona km22E0877 , ES

Entity Type: 98

Trademark Details

Filing Date

December 24, 2024

Registration Date

Not Registered

Goods & Services

Scientific and technological services as well as research and design related thereto, namely, scientific research, development, and design services relating to pharmaceuticals; industrial analysis and research services in the field of chemistry for medical purposese; pharmaceutical research services; research and development services in chemistry; research services relating to cosmetics; pharmaceutical research and product development services

Chemical products for use in industry specifically for biotechnological product development; chemical products for use in pharmaceutical product manufacture; chemical products for manufacturing cosmetics; biological preparations for industry and science

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of cardiovascular diseases, of the central nervous system, namely, encephalitis, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, of respiratory diseases, namely, respiratory infections, asthma, bronchitis, pneumonia, of eating disorders, of musculo-skeletal disorders, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, of urological, urogenital and urinary disorders, of dermatological diseases, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, rosacea, blotches; pharmaceutical products for medical use to treat metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases, gynecological conditions and conditions of the reproductive system; pharmaceutical products for veterinary use, namely, veterinary pharmaceutical preparations for the treatment of metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases and conditions of the reproductive system; pharmaceutical products for skin care; hygienic and sanitary products for medical use namely, disinfectants and sanitary sterilizing preparations; dietetic substances for medical use; dietetic substances namely, dietetic preparations adapted for veterinary use, food supplements for humans and animals; biological preparations for medical and veterinary use specifically cytostatic agents, hormones, diagnostic agents for medical purposes, anti-infective agents, blood clotting agents, blood anticoagulant agents, , veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia, respiratory infections, eye infections, topical infections

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 3, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 3, 2026 GNSL
SUSPENSION LETTER WRITTEN
Feb 3, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 2, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 2, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 2, 2026 TROA
REFUSAL PROCESSED BY IB
Aug 23, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 1, 2025 RFCS
REFUSAL PROCESSED BY MPU
Aug 1, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 11, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jun 10, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 10, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 24, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 24, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 20, 2025 REPR